Transcatheter Treatment of Chronic Aortic Regurgitation Using the Novel J-Valve System: 6-Months Results from a Transfemoral Early Feasibility Study (Edwards Lifesciences)

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Consultant Fee/Honoraria/Speaker's Bureau - Medtronic; Edwards Lifesciences; Abbott</li><li>Consultant Fee/Honoraria/Speaker’s Bureau - Boston Scientific Corporation; Anteris; Capstan Medical; B. Braun</li><li>Equity/Stock(s)/Options - Capstan Medical</li><li>Proctor - Abbott; Edwards Lifesciences</li><li>Advisory Board - Boston Scientific Corporation; Medtronic</li></ul>